Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Enlivex Therapeutics Ltd (ENLV)

Enlivex Therapeutics Ltd (ENLV)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 141,840
  • Shares Outstanding, K 15,760
  • Annual Sales, $ 0 K
  • Annual Income, $ -11,820 K
  • 60-Month Beta 1.06
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.62
Trade ENLV with:

Options Overview

Details
  • Implied Volatility 120.58%
  • Historical Volatility 47.95%
  • IV Percentile 21%
  • IV Rank 9.17%
  • IV High 309.85% on 11/09/20
  • IV Low 101.46% on 01/07/21
  • Put/Call Vol Ratio 1.57
  • Today's Volume 77
  • Volume Avg (30-Day) 83
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 4,318
  • Open Int (30-Day) 4,435

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.26
  • Number of Estimates 1
  • High Estimate -0.26
  • Low Estimate -0.26
  • Prior Year -0.23
  • Growth Rate Est. (year over year) -13.04%

Price Performance

See More
Period Period Low Period High Performance
1-Month
8.92 +0.90%
on 06/24/21
10.12 -11.07%
on 06/15/21
-0.41 (-4.36%)
since 05/24/21
3-Month
8.30 +8.43%
on 05/13/21
12.50 -28.00%
on 04/29/21
-2.42 (-21.19%)
since 03/24/21
52-Week
4.49 +100.45%
on 08/24/20
29.40 -69.39%
on 02/08/21
+2.66 (+41.96%)
since 06/24/20

Most Recent Stories

More News
Enlivex Annouces Participation in A.G.P.'s Upcoming 2021 Virtual Summer Healthcare Symposium

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that members of the Company's management team will participate...

ENLV : 9.00 (-2.39%)
Enlivex Announces Issuance of New European Patent Covering Therapeutic Compositions of Allocetra and CAR-T Immunotherapies for Inhibition or Reduction of Cytokine Storms Associated with CAR-T Therapies for Cancer

- Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors,...

ENLV : 9.00 (-2.39%)
Enlivex to Present at the Jefferies 2021 Virtual Healthcare Conference

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the Jefferies 2021 Virtual...

ENLV : 9.00 (-2.39%)
Enlivex Announces Issuance of New Canadian Patent Covering Pharmaceutical Compositions, Manufacturing Methods and Uses of Allocetra Immunotherapy

Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors,...

ENLV : 9.00 (-2.39%)
Enlivex Awarded Second Israel Innovation Authority Grant to Support the Clinical Development of Allocetra in Sepsis

Grant provides $1.1 million in non-dilutive funding for 2021

ENLV : 9.00 (-2.39%)
Enlivex Announces Research Collaboration with Yale Cancer Center to Assess Synergistic Effect of Allocetra(TM) in Combination with Immune Checkpoint Inhibitors

EQNX::TICKER_START (NASDAQ:ENLV), EQNX::TICKER_END

ENLV : 9.00 (-2.39%)
Enlivex Announces Upcoming Virtual Investor Conference Participations

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company, today announced that Company management will present at the following investor...

ENLV : 9.00 (-2.39%)
Enlivex Receives Notice of Allowance for Japanese Patent Application Covering the use of Allocetra in Combination with CAR-T Therapies

Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors,...

ENLV : 9.00 (-2.39%)
Enlivex and Mount Sinai Health System Announce Research Collaboration for the Development of Allocetra in Combination with Immune Checkpoint Inhibitors

-- Collaboration aims to evaluate the potential of Allocetra(TM) in combination with immune-checkpoint inhibitors in solid cancer patients that do not respond to stand-alone checkpoint inhibitor therapies...

ENLV : 9.00 (-2.39%)
Enlivex Receives Notice of Allowance for Chinese Patent Application Covering Allocetra Immunotherapy

Enlivex Therapeutics Ltd., (Nasdaq: ENLV, the "Company"), a clinical-stage macrophage reprogramming immunotherapy company targeting diseased macrophages in patients with sepsis, COVID-19 and solid tumors,...

ENLV : 9.00 (-2.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

The market is approaching oversold territory. Be watchful of a trend reversal.

See More Share

Business Summary

Enlivex is a clinical stage immunotherapy company, developing an allogeneic drug pipeline for immune system rebalancing. Immune system rebalancing is critical for the treatment of life-threatening immune and inflammatory conditions which involve hyper-expression of cytokines (Cytokine Release Syndrome)...

See More

Key Turning Points

3rd Resistance Point 9.61
2nd Resistance Point 9.45
1st Resistance Point 9.23
Last Price 9.00
1st Support Level 8.85
2nd Support Level 8.69
3rd Support Level 8.47

See More

52-Week High 29.40
Fibonacci 61.8% 19.88
Fibonacci 50% 16.94
Fibonacci 38.2% 14.01
Last Price 9.00
52-Week Low 4.49

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar